A large disparity of opinions emerged between experts regarding serum PTH levels above which rhGH treatment should not be started in children with growth failure and CKD, with only 26% of them complying with the 2019 clinical practice recommendations (2) (Figure 5). This evidence concerns the gene PTH and chronic kidney disease.